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Open access under the ElseviThe purpose of this prospective study was to determine the effect of the low-level laser in the prevention
and treatmentofmucositis inheadandneckcancerpatients.A total of70patientswithmalignantneoplasms
in the oral cavity or oropharynx were evaluated. The patients were randomized into two low-level laser
therapy groups: Group 1 (660 nm/15 mW/3.8 J/cm2/spot size 4 mm2) or Group 2 (660 nm/5 mW/
1.3 J/cm2/spot size 4 mm2) starting on the ﬁrst day of radiotherapy. Oral mucositis was assessed daily
and weekly using the NCI and WHO scales. Oral pain was scored daily with a visual analogue scale before
laser application.The patients inGroup 1 had amean time of 13.5 days (range 6–26 days) to present muco-
sitis grade II, while the patients in Group 2 had a mean time of 9.8 days (range 4–14 days) (both WHO and
NCI p = 0.005). In addition, Group 2 also presented a higher mucositis grade than Group 1 with signiﬁcant
differences found in weeks 2 (p = 0.019), 3 (p = 0.005) and 4 (p = 0.003) for WHO scale and weeks 2
(p = 0.009) and 4 (p = 0.013) for NCI scale. The patients in Group 1 reported lower pain levels (p = 0.004).
Low-level laser therapy during radiotherapy was found to be effective in controlling the intensity of muco-
sitis and pain.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction In the same way, low-level laser therapy (LLLT) has been inves-Oral mucositis is an acute complication resulting from antineo-
plastic treatment that affects patients submitted to chemotherapy
in high doses and radiotherapy (RXT) in the head and neck region.
Over the last 5–10 years, the prevalence of oral mucositis has in-
creased due to new chemotherapy and RXT protocols.1 Among pa-
tients with head and neck tumors treated with RXT, 90–97%
present some degree of mucositis and generally 50% develop grade
III or grade IV mucositis. In addition, 9–19% of oncological treat-
ment interruptions are due to mucositis.2,3
Treatment for oral mucositis is still essentially palliative.4 Re-
cently, Palifermin (Kepivance), a keratinocyte growth factor,
was approved by the US Food and Drug Administration. It is used
in the prevention of mucositis in patients with hematological dis-
eases undergoing conditioning regime for bone marrow transplan-
tation.5–8 Nevertheless, for radio-induced oral mucositis, there is
no efﬁcient treatment.9t – Hospital A.C. Camargo, R:
o, SP, Brazil. Tel.: +55 11 2189
s).
er OA license.tigated in recent studies for the prevention and treatment of oral
mucositis in patients submitted to bone marrow transplantation
(BMT).10–13 The Multinational Association of Supportive Care in
Cancer (MASCC) has suggested the use of laser for mucositis asso-
ciated with chemotherapy but makes no speciﬁc recommendation
about the use of laser for radio-induced mucositis.1
The laser mechanism has been described as an activation of en-
ergy production by the cytochromes in the mitochondria of oral
mucosa cells, by the transmission of electrons.14 The laser pro-
motes rapid regeneration of the myoﬁbroblasts originating in the
ﬁbroblasts and the growth factors of these ﬁbroblasts maintain re-
pair and cytotoxic protection.15
Thereare fewstudies about laser therapy in theprevention/treat-
ment of mucositis caused by RXT.16–21 Despite the different proto-
cols used, these studies have shown that LLLT can produce some
beneﬁt to reduce the severity of oral mucositis and pain. Bensadoun
et al.16 used He–Ne laser (632.8 nm/60 mW/30 s), Arora et al.18 also
used He–Ne laser (632.8 nm/10 mW/1. 8 J/cm2) daily. Zanin et al.20
used a laser diode twice a week (660 nm/30 mW/2 J). Simões
et al.19 used LLLT (InGaAlP 660 nm/40 mW/6 J/cm2) alone or associ-
ated with high power laser. However, questionable results were
found by Gouvea de Lima et al.21 that used LLLT (InGaAlP/660 nm/
10 mW/spot size 4 mm2) every day before radiotherapy.
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prevention and treatment of radio-induced oral mucositis in pa-
tients with oral and oropharynx cancer.
Patients and methods
Characterization of the study
This study consisted of a randomized, double-blind, controlled
clinical trial. A total of 70 patients, between February 2008 and
December 2009, met the criteria for participation in the study.
The study was approved by the Ethics Committee of Hospital A.C.
Camargo, São Paulo, Brazil (no. 988/07) and all patients signed an
informed consent form.
Inclusion criteria
Patients with malignant neoplasms in the oral cavity and/or
oropharynx were submitted to conventional three-dimensional
conformal radiotherapy (RTC3D) or intensity modulated radiation
therapy (IMRT) with doses in facial ﬁelds equal to or higher than
4000 cGy, either exclusively or associated with chemotherapy (cis-
platin 100 mg/m2 every 21 days or 50 mg/m2 per week).
Exclusion criteria
Patients who have previously been submitted to RXT in the
head and neck or using any cytoprotector.
Study design
Two randomization lists, in blocks of 6 patients, were generated
by a program prepared in SAS, version 8.02. The patients were
stratiﬁed by chemotherapy treatment (yes or no). Thus, a total ofTable 1
Clinical features of the 70 patients evaluated in both groups.
Variables Group 1
N %
Gender Male 25 71.4
Female 10 28.6
Age (years) Range 22–94
Mean ± SD 55.2 ± 4.5
Tumor location Mouth Tongue 12 34.3
Buccal 3 8.6
Palate 2 5.7
Trigone 1 2.9
Gingiva 1 2.9
Floor 4 11.4
Lip 1 2.9
Oropharynx 11 31.4
Clinical stage I 4 11.4
II 6 17.1
III 11 31.4
IV 14 40.0
Treatment Sur + RxT 14 40.0
Sur + RxT + CH 10 28.6
RxT + CH 8 22.9
RxT 3 8.6
RxT type 2D 7 20.0
3D 15 42.9
IMRT 13 37.1
RxT dose (GY) 60–64 14 51.8
65–72 13 48.2
CH dose (mg/m2) 50 03 16.7
100 15 83.3
SD – standard deviation; CH – chemotherapy; RxT – radiotherapy; Sur – surgery.70 patients were randomized by the sealed envelope method and
allocated into two groups distributed in a similar manner.
Group 1 consisted of 35 patients (25 males and 10 females),
age-range between 22 and 94 years (mean 56.2 ± 14.5). With re-
gard to tumor location, 24 were located in the oral cavity (12 in
the tongue) and 11 in the oropharynx. According to the proposed
treatment, 14 patients were submitted to surgery and radiother-
apy, 10 patients to surgery followed by radiotherapy and chemo-
therapy, eight patients to radiotherapy and chemotherapy and
three patients received radiotherapy exclusively. Regarding che-
motherapy, 15 patients were submitted to cisplatin 100 mg/m2
and three patients to cisplatin 50 mg/m2 (Table 1). Among the 35
patients, eight patients did not complete the study and were ex-
cluded. Two patients failed to attend the laser therapy sessions
(one patient was receiving radiotherapy at another institution
and another was conﬁned to a wheelchair), one patient changed
the scheme of chemotherapy from cisplatin to cetuximab, one pa-
tient died and four patients were randomized but did not begin
RXT until conclusion of the study. A subsequent preliminary anal-
ysis showed statistical signiﬁcance between the groups indicating
that the study could be concluded.
Group 2 consisted of 35 patients (21 males and 14 females),
age-range between 35 and 79 years (mean 58.1 ± 10.9). In regard
to tumor location, 25 were located in the oral cavity (11 in the ton-
gue) and 10 in the oropharynx. According to the proposed treat-
ment, 12 patients were submitted to surgery and radiotherapy,
17 patients to surgery followed by radiotherapy and chemother-
apy, ﬁve patients to radiotherapy and chemotherapy and one pa-
tient received radiotherapy exclusively. Regarding chemotherapy,
18 patients were submitted to cisplatin 100 mg/m2 and four pa-
tients to cisplatin 50 mg/m2 (Table 1). Eight out of 35 patients were
excluded from the study, of which four patients missed the laser
sessions without justiﬁcation, one patient altered the treatment
due to local recurrence, one patient had gastrostomy complica-Group 2 Total p-Value
N % N %
21 60 46 65.7 0.314
14 40 24 34.3
35–79 22–94 0.541
58.1 ± 10.1 57.1 ± 12.8
11 31.4 23 32.9 0.990
4 11.4 7 10.0
4 11.4 6 8.6
1 2.9 2 2.9
1 2.9 2 2.9
4 11.4 8 11.4
0 0.0 1 1.4
10 28.6 21 30
0 0 4 5.7 0.140
6 17.1 12 17.1
10 28.6 21 30.0
19 54.3 33 47.1
12 34.3 26 37.1 0.300
17 48.6 27 38.6
5 14.3 13 18.6
1 2.9 4 5.7
3 8.6 10 14.3 0.308
20 57.1 35 50.0
12 43.3 25 35.7
18 66.6 32 59.3 0.450
9 33.4 22 40.7
05 22.7 08 20.0 0.709
17 77.3 32 80.0
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did not begin RXT until conclusion of the study.
Prophylactic laser applications
In both groups, the appliance used was a gallium aluminum–
arsenate (InGaAlP) diode laser (Twin laser – MMOptics, MMOp-
tics Ltda., São Carlos, São Paulo, Brazil). For Group 1, the laser illu-
mination consisted of a continuous 660 nm wavelength, power
15 mW, spot size 4 mm2 and energy density delivered to the oral
mucosa was 3.8 J/cm2 For Group 2, the laser illumination consisted
of a continuous wavelength 660 nm, power 5 mW, spot size 4 mm2
and 1.3 J/cm2 of energy density delivered to the oral mucosa. The
device and light color were identical for both groups.
In both groups, each anatomic site was illuminated for 10 s. All
applications were performed by a single professional, blinded to
the laser groups. The anatomical areas of the oral mucosa were
irradiated according to the procedure described by Jaguar et al.13
The tumor area (or previous tumor area) was excluded from the
ﬁeld of laser illumination.
In both groups, the applications were realized daily, ﬁve consec-
utive days per week, starting on the ﬁrst day of RXT (always before
the radiation sessions). All patients that participated in the study re-
ceived preventive LLLT in the oral normalmucosa. The patients who
developed grade II mucositis (in both groups) stopped the prophy-
lactic protocol andbegan curative laser therapy (performedwith an-
other device) that consisted of a continuous 660 nm wavelength,
power 15 mW, spot size 4 mm2 and energy density of 3.8 J/cm2
delivered in each ulcerated area of oral mucosa. These patients con-
tinued to be followed-up and evaluated in regard to the degree of
mucositis and pain until the end of RXT treatment.
All patients underwent oral care protocol before starting RXT.
The oral care protocol included oral examination, preventive dental
treatment, instructions for oral care during radiation therapy and
prescription mouthwashes and ﬂuoride (if dentate).
Oral mucositis evaluation
Oral mucositis was evaluated on a daily and weekly basis in
accordance with the classiﬁcation criteria of the National Cancer
Institute (NCI) and the World Health Organization (WHO).22
Oral pain evaluation
In relation to oral pain, the patients were analyzed up to the
30th day of RXT and the pain was evaluated subjectively accordingTable 2
Mean and median of days for the patients develop mucositis grades II
Mucositis Scales Groups N
Grade II WHO 1 25
2 27
NCI 1 25
2 27
Grade III WHO 1 13
2 17
NCI 1 17
2 21
SD – standard deviation.
* Means statistically signiﬁcant.to a visual analog scale (VAS), in which ‘‘0’’ is the absence of pain
and ‘‘10’’ is maximum pain. The patients were instructed to attri-
bute a score to their degree of pain in oral mucositis.
Statistical analysis
The Student’s-t test was used for the comparison of age be-
tween the two groups. The Chi-Square test was used to verify asso-
ciation between the variables gender, tumor location, Group 1 or
Group 2, type and dose of RXT. The ordinal logistic regression mod-
el was used to verify whether there was difference in staging be-
tween the two groups, as well as to compare the WHO and NCI
degree of mucositis between the two groups. In the comparison
of pain intensity between the two groups, the area under the curve
of pain scores of the ﬁrst 30 days of evaluation was calculated. The
areas under the curve were compared by means of the Student’s-t
test.
The statistical software programs used in the analyses were
XLSTAT 2009 and Minitab 14.Results
Daily evaluation of mucositis
According to theWHO scale, the patients in Group 1 had a mean
time of 13.5 days (range 6–26 days) to present mucositis grade II,
and the patients in Group 2 had a mean time of 9.8 days (range
4–14 days) (p = 0.005). Similar data were also observed with the
NCI classiﬁcation (Table 2).
For development of mucositis grade III (WHO scale), the pa-
tients in Group 1 and in Group 2 had a mean time of 23.6 days
(range 11–31 days) and 17.1 days (range 10–31 days) (p = 0.014),
respectively. According to NCI scale, the patients had a mean time
of 19.1 days (range 11–32 days) and 17.2 days (range 8–33 days)
(p = 0.498), respectively (Table 2).
Weekly evaluation of mucositis
In the weekly comparison in accordance with the WHO scale,
Group 2 presented a signiﬁcantly higher mean of mucositis grade
than Group 1 in weeks 2 (p = 0.019), 3 (p = 0.005) and 4
(p = 0.003) (Table 3) (Fig. 1A). In addition, only one patient in
Group 1 presented mucositis grade IV, which occurred in week 5
of RXT. However, in Group 2, six patients (22.2%) had mucositis
grade IV.and III.
Mean ± SD (range) Median p-Value
13.5 ± 5.7 11.0 0.005*
(6–26)
9.8 ± 2.6 9.0
(4–14)
13.5 ± 5.7 11.0 0.005*
(6–26)
9.8 ± 2.6 9.0
(4–15)
23.6 ± 7.2 26.0 0.014*
(11–31)
17.1 ± 6.0 14.0
(10–31)
19.1 ± 6.9 18.0 0.498
(11–32)
17.5 ± 7.5 15.0
(8–33)
Table 3
Mean grade of mucositis per week, during 7 weeks of treatment according to WHO and NCI.
Week(s) N (patients) Group 1 Group 2 p-Value (WHO) p-Value (NCI)
Mean (WHO) Mean (NCI) Mean (WHO) Mean (NCI)
1 27 0.00 ± 0.00 0.00 ± 000 0.11 ± 0.42 0.11 ± 0.42 – –
2 27 0.78 ± 0.93 0.78 ± 0.93 1.41 ± 0.93 1.56 ± 1.09 0.019 0.009
3 27 1.59 ± 0.97 1.74 ± 1.10 2.30 ± 0.47 2.33 ± 0.48 0.005 NS
4 27 1.52 ± 0.85 1.63 ± 0.97 2.30 ± 0.87 2.33 ± 0.88 0.003 0.013
5 27 1.85 ± 0.82 1.93 ± 0.87 2.19 ± 0.88 2.22 ± 0.89 NS NS
6 27 2.15 ± 0.72 2.15 ± 0.77 2.19 ± 0.96 2.26 ± 0.98 NS NS
7 17 2.35 ± 0.61 2.44 ± 0.62 2.00 ± 0.79 2.12 ± 0.86 NS NS
Figure 1 Mean grade of mucositis evaluated weekly in both Groups 1 and 2 according toWHO scale (A) and NCI scale (B). Evaluation of the severity of oral mucositis between
Groups 1 and 2 according to WHO (C) and NCI scales (D).
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ing NCI mucositis in weeks 2 (p = 0.009) and 4 (p = 0.013). The
grade of mucositis in Group 2 was higher than it was in Group 1
(Table 3) (Fig. 1B).
The percentage of patients that presented grade I was higher in
Group 1 in the two classiﬁcations, for grades II, III and IV the oppo-
site occurred. The NCI classiﬁcation had a higher percentage of
grade III than the WHO classiﬁcation (Fig. 1C and D).Pain
Up to the ﬁfth day of evaluation, no patient in Group 1 com-
plained of oral pain, but in Group 2 two patients reported pain.
The highest pain scores occurred during the third week in both
groups (Fig. 2). Importantly, the mean intensity of pain was always
higher for Group 2 (p = 0.004).Discussion
Radio-induced oral mucositis is the main acute effect in patients
undergoing RXT for treatment of head and neck tumors. At present,
there is no therapy capable of completely preventing mucositis and
LLLT is a new therapeutic option for its management. Considering
mucositis related to BMT or to high doses of chemotherapy, laser
therapy has been effective in the prevention and healing of le-
sions.10–13 In addition, some studies16–18 have also conﬁrmed itsefﬁcacy in diminishing the severity and delaying the manifestation
of radio-induced mucositis.
The ﬁrst study that evaluated the LLLT in radio-induced oral
mucositis was conducted by Bensadoun et al.16 where the patients
were divided into two groups receiving laser or sham light. All
applications were performed by the same operator, but this person
did not participate in the evaluation and scoring of mucositis.
Otherwise, the present study consisted of a randomized, double-
blinded clinical trial to evaluate the effects of the LLLT in which a
single operator performed both devices that emitted light with
similar color. Group 2 consisted of a continuous wavelength
660 nm, power 5 mW and 1.3 J/cm2 of energy density delivered
in each point of the oral mucosa. According to the manufacture
(MMOptics), this illumination has minimal biological effects.
Group 1 consisted of a continuous 660 nm wavelength, power
15 mW with 3.8 J/cm2energy density delivered in each point of
the oral mucosa. Thus, this study was the ﬁrst to compare the ef-
fects of laser therapy and light with no or minimal effects in cells.
In addition, for ethical reasons, independent of Groups 1 or 2, if the
patient presented grade II mucositis, a curative laser therapy
(wavelength of 660 nm, 15 mW potency, and energy density of
3.8 J/cm2 per point) was started according to the protocol of the
Stomatology Department at Hospital A.C. Camargo. However, the
patient continued to be followed in their original group.
In the present study, the patients were evaluated on a daily and
weekly basis. In our opinion, the daily evaluation was important to
show the precise development of ulcerated mucositis (grade II)
from the oral normal mucosa. Thus, Group 1 presented oral ulcer
Figure 2 Mean score of oral pain evaluated daily in both Groups 1 and 2.
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4 days later than Group 2, according to both WHO and NCI scales.
Arora et al.18 also evaluated their patients on a daily basis. How-
ever, the authors presented their results scored in weekly evalua-
tion as in the Bensadoun study.
In the current study, considering the weekly basis, Group 1
developed lower mucositis grades than Group 2, with statistical
signiﬁcance between the second to fourth weeks (according to
both WHO and NCI scales). In the adjacent weeks, both Groups 1
and 2 presented similar mucositis grades. These data can clearly
be observed in Fig. 1A and B. On the other hand, Bensadoun
et al.16 found statistical signiﬁcance in the fourth to seventh and
Arora et al.18 in the second to seventh weeks. In addition, we inves-
tigated the probable explanations for this difference. First, as was
commented above, when the patients presented grade II mucositis,
independent of the group, they received curative laser therapy
with the same speciﬁcations in both groups. Another fact, RXT
interruption occurred in six patients in Group 2 against one in
Group 1 (due to mucositis) and consequently, the mucositis inten-
sity ameliorated in these patients.
Arora et al.18 also showed that all patients independent of the
group presented ulcerated oral mucositis (grade II mucositis). In
addition, four patients (30.8%) in the control group developed
mucositis grade IV, whereas in the laser group, no patient had this
grade. Similarly, in our study only two patients in Group 1 did not
present ulcerated mucositis. Nevertheless, one (3.7%) patient in
Group 1 developed Grade IV oral mucositis and six (22.2%) patients
in Group 2 had their treatment interrupted due to grade IV muco-
sitis. Different than in the study of Bensadoun et al.16 no patient
presented oral mucositis grade IV, neither in Group 1 nor Group
2. A possible explanation could be that in the Bensadoun study,
nine out of 30 patients (ﬁve in placebo group and four in laser
group) had primary tumors located in the hypopharynx; such pa-
tients usually present a lower incidence of oral mucositis. Likewise,
Gouvea de Lima et al.21 presented 35 out of 74 patients (18 in pla-
cebo group and 17 in laser group) with primary tumors located in
different sites of the oral cavity and oropharynx. This could explain
the low rate of mucositis grade III–IV. Despite the signiﬁcant differ-
ence from week 1, Zanin et al.20 had 30 out of 72 patients in their
study (16 in control group and 14 in laser group) and no patient
presented grade IV mucositis. Arora et al.18 analyzed only patients
with oral cavity tumors and in our study we randomized patients
with malignant neoplasms in the oral cavity and/or oropharynx.
With regard to pain, the present study showed a signiﬁcant
reduction in pain scores. Patients were evaluated on a daily basis,
always before the application of laser therapy. On average, Group
1 always presented lower pain scores than Group 2. Bensadounet al.16 evaluated the patients once a week by means of a modiﬁed
visual analog scale. The highest pain scores were found in the ﬁfth
week of treatment, and the group treated with laser always pre-
sented a lower mean than the group treated with sham light. Arun
Maya et al.17 had their patients evaluated by a professional who
did not know which group was having the laser treatment. The
pain scores were also signiﬁcantly lower for the group treated with
laser (2.6 ± 0.64) than for the control group (6.68 ± 1.44). Arora
et al.18 examined the patients in the morning before the RXT ses-
sions through a numerical scale and consumption of analgesics,
according to the WHO analgesic scale. Although a signiﬁcant
reduction of pain scores was observed in the laser group, no signif-
icant difference was found, between the groups, in regard to the
consumption of analgesics.
In summary, LLLT appears to present promising results, both in
control of the intensity of mucositis and in the pain related to the
mucositis. However, further studies are necessary to deﬁne the
dose, application time and number of sessions in patients submit-
ted to oncological treatments.Conﬂict of interest statement
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